Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 33 Breast Neoplasms 21 Prostatic Neoplasms 17 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 10 Neoplasms 7 Neoplasm Metastasis 6 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Salivary Gland Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Nasopharyngeal Carcinoma 3 Melanoma 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Carcinoma 3 Recurrence 2 Osteosarcoma 2 Non-Muscle Invasive Bladder Neoplasms 2 Lymphoid Interstitial Pneumonia 2 Laryngeal Neoplasms 2 HER2-positive Breast Cancer 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2

Interventions

Gemcitabine 3 Cisplatin 3 Carboplatin 3 pembrolizumab 2 erdafitinib 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Tiragolumab 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Urothelial Cancer × Docetaxel × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡